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ABSTRACT
Purpose Predicting target site drug concentration in the brain
is of key importance for the successful development of drugs
acting on the central nervous system. We propose a generic
mathematical model to describe the pharmacokinetics in
brain compartments, and apply this model to predict human
brain disposition.
Methods A mathematical model consisting of several physi-
ological brain compartments in the rat was developed using
rich concentration-time profiles from nine structurally diverse
drugs in plasma, brain extracellular fluid, and two cerebrospi-
nal fluid compartments. The effect of active drug transporters
was also accounted for. Subsequently, the model was translat-
ed to predict human concentration-time profiles for acetamin-
ophen and morphine, by scaling or replacing system- and
drug-specific parameters in the model.
Results A common model structure was identified that ade-
quately described the rat pharmacokinetic profiles for each of
the nine drugs across brain compartments, with good preci-
sion of structural model parameters (relative standard error
<37.5%). The model predicted the human concentration-
time profiles in different brain compartments well (symmetric
mean absolute percentage error <90%).
Conclusions A multi-compartmental brain pharmacokinetic
model was developed and its structure could adequately de-
scribe data across nine different drugs. The model could be
successfully translated to predict human brain concentrations.
KEY WORDS blood-brain barrier . central nervous system
(CNS) . human prediction . pharmacokinetics . translational
model
ABBREVIATIONS
BBB Blood–brain barrier
BCSFB Blood–cerebrospinal fluid barrier
brainECF Brain extracellular fluid compartment
brainICF Brain intracellular fluid compartment
CNS Central nervous system
CSF Cerebrospinal fluid
CSFCM Compartment of cerebrospinal fluid in cisterna
magna
CSFEVD Compartment of cerebrospinal fluid obtained by
external-ventricular drainage
CSFLV Compartment of cerebrospinal fluid in lateral
ventricle
Electronic supplementary material The online version of this article
(doi:10.1007/s11095-016-2065-3) contains supplementary material, which is
available to authorized users.
* Elizabeth C. M. de Lange
ecmdelange@lacdr.leidenuniv.nl
2 Quantitative Sciences, Janssen Research & Development, a Division of
Janssen Pharmaceutica NV, Beerse, Belgium
3 Division of Pharmacokinetics, Toxicology and Targeting, University of
Groningen, Groningen, The Netherlands
4 Department of Clinical Pharmacology & Exploratory
Development, Astellas Pharma BV, Leiden, The Netherland
5 Department of Medicine and Pharmacy, University of
Poitiers, Poitiers, France
6 Department of Anaesthesiology and Intensive Care Medicine, University
Hospital Center of Poitiers, Poitiers, France
7 Leiden University Gorlaeus Laboratories, Einsteinweg 55,
2333CC Leiden, The Netherlands
Pharm Res (2017) 34:333–351
DOI 10.1007/s11095-016-2065-3
1 Division of Pharmacology, Cluster Systems Pharmacology, Leiden
Academic Centre for Drug Research, Leiden University,
Leiden, The Netherlands
CSFSAS Compartment of cerebrospinal fluid in subarach-
noid space
CSFTFV Compartment of cerebrospinal fluid in third and
fourth ventricle
ECF Extracellular fluid
EVD External-ventricular drainage
ICF Intracellular fluid
IPRED Individual prediction
PF Perfusion fluid
PK Pharmacokinetic
PRED Population predictions
SABBB Surface area of blood–brain barrier
SABCSFSB Surface area of blood–cerebrospinal barrier
SMAPE Symmetric mean absolute percentage error
SPE Solid phase extraction
TBI Traumatic brain injury
INTRODUCTION
Central nervous system (CNS) drug development suffers from
91% attrition rate and especially the success rate in phase II is
very low (1,2). The primary reasons for attrition are safety
issues (3). Although the underlying physiological and pharma-
cological reasons for such failures are often not fully known
they are likely related to a lack of knowledge or failure to
account for a combination of on- and off-target site concen-
trations, target interaction and downstream signal processing.
The first step in this cascade, obtaining quantitative insight
into CNS target site concentration kinetics, is already a major
challenge, and has been suggested as a major factor contrib-
uting to failure of novel drug candidates (4). During clinical
drug development, typically only drug plasma concentrations
are considered as marker for drug exposure, because quanti-
fying drug concentrations in the brain is challenging. Hence,
the ability to predict brain concentrations based on plasma
data is highly relevant to further optimize CNS drug
development.
The prediction of brain target site concentrations is con-
trolled by several factors. First, the poorly penetrable blood-
brain barrier (BBB) and the blood-cerebrospinal barrier
(BCSFB) (5) limit passage of drugs from the systemic circula-
tion into the brain. These barriers are associated with limited
passive diffusion, and in addition various active transport and
drug metabolism processes that systematically administered
drugs need to pass. Second, the brain can be further
subdivided into several distinct physiological compartments,
including the brain extracellular fluid (ECF), brain intracellu-
lar fluid (ICF), and multiple cerebrospinal fluid (CSF) com-
partments. The specific disposition characteristics across these
specific compartments further determines drug target site con-
centrations. Third, CNS drug target site concentrations are
mediated by physiological flows including the microvascular
blood flow, and brain ECF and CSF flows. Lastly, drug pro-
tein binding and the localized pH in specific sub-
compartments further affect ultimate brain target site
concentrations.
Passive drug transport processes are mediated through a
combination of drug permeability properties, trans-
membrane transport routes, and the surface areas of the
BBB (SABBB) and BCSFB (SABCSFB) (5). Active drug transport
is mediated by transport proteins such as P-glycoprotein (P-
gp), multidrug resistance-associated protein (MRPs), organic
anion transporters (OATs), and organic anion transporting
polypeptides (OATPs). Even though the function and locali-
zation of these transporters has been extensively investigated
in in-vitro and in-vivo studies, their precise functions is in some
cases not fully understood (6).
Several experimental preclinical models have been devel-
oped to assess drug distribution to brain compartments. These
models differ in terms of temporal and spatial resolution, and
in their consideration of drug protein binding (7–10). For ex-
ample, the combinatorial mapping approach has been recent-
ly introduced using unbound drug concentration with the
brain slice technique (10,11). This approach can predict un-
bound drug CNS exposure at steady state in multiple brain
compartments, but does not allow temporal characterization
of drug concentration changes. Positron emission tomography
(PET) is sometimes used also clinically, as a non-invasive im-
aging method to visualize spatiotemporal drug distribution in
the brain. However, PET scan signals cannot distinguish par-
ent compounds from their metabolites, or bound and un-
bound drug compounds in the brain (12). Finally, microdial-
ysis allows serial sampling in multiple physiological compart-
ments of unbound drug concentrations, hence is suited to
characterize the time profile of drug concentrations in the
brain (13).
In order to capture the time profile and complexity of
interacting factors governing drug distribution across brain
compartments as determined bymicrodialysis methods, math-
ematical modeling represents an indispensable tool.
Specifically, physiologically based pharmacokinetic (PBPK)
models are of interest, as these models aim to distinguish be-
tween system- and drug-specific parameters, allowing for
translational predictions by scaling or replacing system- or
drug-specific parameters from the rat to man (14). Several
(semi-) PBPK models for CNS drug distribution have been
published, with different levels of complexity (15–20).
However, these models did not yet include validations of pre-
dicted human CNS concentrations (21). Recently, Gaohoa
et al published a CNS PBPK model, which consists of four
compartments such as brain blood volume, brain mass, crani-
al CSF and spinal CSF. This model was validated with human
acetaminophen and phenytoin data. However, a limitation of
this model is the lack of consideration of a brain extracellular
fluid compartment (brainECF), which is of critical importance
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for prediction of receptor binding kinetics for drugs acting on
membrane bound receptors and ultimately drug efficacy (22).
Previously we have developed separate semi-physiological
CNS PBPK models for three drugs based on microdialysis
experiments in rats, which included unbound drug
concentration-time profiles across multiple brain compart-
ments (23–25). These models described the data well, but
resulted in different individual model structures for each of
these drugs.
The purpose of the current work was to develop a more
generally applicable model structure that can be used to pre-
dict drug target site concentration-time profiles in human
brain compartments based on rat pharmacokinetic (PK) stud-
ies. To this aim, we used published and newly generated
datasets for a larger number of drugs, and we performed rig-
orous model validation on external datasets. Furthermore, the
impact of key drug transporters was also included in our mod-
el. Finally, we investigated the performance of the developed
model structure to predict human brain concentration-time
profiles for acetaminophen and morphine.
MATERIALS AND METHODS
Data for Model Development
An overview of experimental data for nine compounds with
different physicochemical characteristics used for model de-
velopment is provided in Table I. The physicochemical char-
acteristics of the nine compounds are provided in Table SI.
Data on 6 compounds were previously published, as indicated
in Table I. For three compounds (paliperidone, phenytoin and
risperidone), data were newly produced after single intrave-
nous administration, as described below.
For some of the drugs, active transport inhibitors were co-
administered intravenously to characterize the effect of P-gp,
MRP, OATs and OATPs, as indicated in Table I. The trans-
port inhibitors included were probenecid as an inhibitor of
MRPs, OATs and OATPs, and GF120918 or tariquidar as
inhibitor of P-gp.
Data for External Model Validation
For an external validation of the model, we used two separate
rat datasets for acetaminophen and remoxipride, as indicated
in Table I. The acetaminophen data was previously pub-
lished, the remoxipride data was newly generated as described
in the experimental section. For acetaminophen and
remoxipride, two separate experimental datasets were avail-
able. For each drug, one of these datasets was used for model
development, whilst the second dataset was used for external
validation. The external validation with these second sets of
data allows assessment of the robustness of our model
predictions with respect to a different experiment and varia-
tion in experimental design.
Animals
Animal study protocols were approved by the Animal Ethics
Committee of Leiden University and all animal experiments
were performed in accordance with the Dutch Law of
Animal Experimentation (for approval numbers see
Table SII). Male Wistar rats (225–275 g, Charles River,
The Netherlands) were housed in groups for a few days (5–
13 days) under standard environmental conditions with ad
libitum access to food (Laboratory chow, Hope Farms,
Woerden, The Netherlands) and acidified water. Between sur-
gery and experiments, the animals were kept individually in
Makrolon type three cages for 7 days to recover from surgical
procedures.
Surgery
Rats were anesthetized (5% isoflurane for induction, 1–2% as
maintenance), and subsequently received cannulas in the fem-
oral artery for serial blood sampling, and in the femoral vein
for drug administration, respectively. Subsequently, microdi-
alysis guides were inserted into different brain locations. The
animals were allowed to recover for 1 week before the exper-
iments were performed. One day before the experiment, the
microdialysis dummies were replaced by microdialysis probes.
For details on guides, probes and locations see Table SII.
Microdialysis and Drug Administration
Experiments generally started at 9:00 a.m. to minimize the
influence of circadian rhythms. Microdialysis probes were
continuously flushed with microdialysis perfusion fluid (PF)
until equilibration before the start of drug administration.
Drugs were administered at t= 0 h by intravenous infusion
through the cannula implanted in the femoral vein. For the
quantification of active drug transport, the active transport
inhibitor was administered before the drug’s administration.
The general procedure of microdialysis is depicted in Fig. 1.
Dosage and infusion time for each drug and the active trans-
port inhibitor were summarized in Table I, and the composi-
tion of microdialysis PF and flow rate of microdialysis PF are
summarized in Table SII.
Bioanalytical methods
The developed analytical methods for risperidone,
paliperidone, phenytoin and remoxipride are described below.
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Chemicals and Reagents
For all procedures, nanopure lab water (18.2 MΩ cm) was
used. All chemicals used were obtained from Sigma Aldrich
(Zwijndrecht, The Netherlands), and analytical grade unless
stated otherwise. The internal standards risperidone-D4 and
paliperidone-D4 were purchased from Toronto Research
Chemicals (Toronto, Ontario, Canada). Remoxipride. HCl
was obtained from TOCRIS (Bristol, United Kingdom).
Tariquidar (TQD, XR9576) was obtained from Xenova
group PLC (Cambridge, United Kingdom). Ammonium for-
mate, ammonium bicarbonate (ULC/MS grade), acetonitrile
(LC-MS grade), methanol, isopropanol, and formic acid
(ULC/MS grade) were obtained from Biosolve B.V.
(Valkenswaard, The Netherlands). Sodium hydroxide was ob-
tained from Baker (Deventer, The Netherlands).
Sample Preparation of Plasma
Risperidone and Paliperidone
The calibration curve was in a range of 5 to 1000 ng/ml.
Quality controls (QC’s) were prepared in blank rat plasma
at three different concentration levels and stored at −20°C.
The lower limit of quantification (LLOQ) for both risperidone
and paliperidone was 5 ng/ml. To 20 μl of plasma, 20 μl of
internal standard solution (risperidone-D4 and paliperidone-
D4) and 20 μl water (or 20 μl calibration solution in the case of
the calibration curve) were added. After brief vortexing, 1 ml
of acetonitrile was added. Brief vortexing and subsequent cen-
trifugation at 10,000 g led to a clear supernatant, which was
transferred to a glass tube and evaporated in the vortex evap-
orator (Labconco, Beun de Ronde, Breda, The Netherlands).
The residue was redissolved in 200 μl of 2% methanol,
10 mM ammonium formate, pH 4.1 and processed in
according to the solid phase extraction (SPE)- liquid chroma-
tography (LC) method.
Phenytoin
20 μl of plasma sample was mixed with 20 μl of water in an
Eppendorf vial. An aliquot of 40 μl acetonitrile was added for
protein precipitation. After centrifugation at 11,000 g for
10min, 40 μl of supernatant wasmixed with 40μl ammonium
acetate buffer (pH 5.0). Calibration was performed by adding
20 μl of calibration solution to 20 μl of blank plasma, using the
same clean-up procedure. The calibration solutions ranged
from 0.2 to 100 μg/ml. 30 μl was injected into the high-
performance liquid chromatography (HPLC) system. The
LLOQ was 250 ng/ml.
Remoxipride
Sample preparation was performed according to Stevens et al
(26). Briefly, 20 μl of sample was mixed with 20 μl of water
and 20 μl internal standard (raclopride). Proteins were precip-
itated with 6% perchloric acid and centrifugation. After addi-
tion of sodium carbonate, 10 μl was injected into the SPE-LC
system.
Sample Preparation for Microdialysates
Risperidone and Paliperidone
The calibration curve for the microdialysis samples was pre-
pared in buffered PF (composition in Table SII). The concen-
trations were in the range of 0.1 to 20 ng/ml. QC’s were
prepared using a different batch of buffered PF. Before injec-
tion of 10 μl into the LC system, the microdialysate samples
were diluted with internal standard solution in a ratio of 1:1 v/
v. The internal standard solution consisted of 100 ng/ml
Phenytoin
0-0.5
-1 0-0.66 -0.42
Administration of the compounds
Administration of the active 
transport inhibitors
-2~0.5 0
9 compounds
Methotrexate
Quinidine
Paliperidone
Risperidone
Phenytoin
Morphine
-2 0
Microdialysate sampling
No active transport inhibitor
Single active transport inhibitor
-2~0.5
Double active transport inhibitor
Start/end of the microdialysis
2~8
2~8
6
8
h
h
h
h
Fig. 1 Microdialysis procedures for
the compounds used for the
development of the multi-
compartmental brain PK model.
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risperidone-D4 and paliperidone-D4 in nanopure water. The
LLOQs for risperidone and paliperidone were 0.4 and
0.2 ng/ml, respectively.
Phenytoin
Calibration curves were made in minimal PF at a concentra-
tion range of 25 to 5000 ng/ml. QC’s were prepared using a
different batch of buffered PF. Of a typical sample that
consisted of 40 μl of microdialysate, 30 μl was injected into
the HPLC system. The LLOQ was 25 ng/ml.
Remoxipride
Calibration curves were prepared in buffered PF. The cali-
bration range was from 1 to 200 ng/ml. QC’s were prepared
using a different batch of buffered PF. Samples were mixed in
a 1:1 v/v ratio with the internal standard raclopride
(100 ng/ml) before injection of 5 μl into the LC system. The
LLOQ was 0.5 ng/ml.
Chromatography
Paliperidone and Risperidone
SPE-LC Method. For plasma samples the SPE-method was ap-
plied. The SPE system consisted of a Hyphere C8 HD, SE
co lumn (10 × 2 mm) (Spa rk Ho l l and , Emmen ,
The Netherlands) in a cartridge holder and served for the
clean-up of the sample. The cartridge holder was connected
to a Gynkotek gradient pump (Thermo Scientific, Breda,
The Netherlands) and a Waters 717 autosampler (Waters,
Etten-Leur, The Netherlands). The MS Surveyor pump from
Thermo Scientific (Breda, The Netherlands) provided the
flow for the LC column, which was the same type as in the
LC-method. The sample was injected onto the SPE, which
was preconditioned with 2% methanol (pH 4.1). After 1 min
of flushing, the SPE was switched into the LC system. After
4 min, the SPE was cleaned with 98% methanol (pH 4.1) for
2 min and reconditioned with 2% methanol (pH 4.1). The
flow of the SPE pump was 0.75 ml/min. The flow of the LC
system was 0.25 ml/min. The gradient was from 10 to 90%
methanol (1–8.5 min after injection). The SPE column was
used for a maximum of 240 injections.
LC-Method. For microdialysates, LC-Method was applied.
The separation of the active compounds was possible using
Hyper Clone HPLC column (3 μm BDS C18 130 Å) from
Phenomenex (Utrecht, The Netherlands) placed at 40°C. The
LC system was used at a flow of 0.25 ml/min using a linear
gradient from 20 to 74% methanol (1–6 min after injection).
Before the next injection, the column was re-equilibrated with
20% methanol for 2 min.
Phenytoin
HPLC Method and Detection. For both plasma and
microdialysates samples an HPLC method was used. The
mobile phase consisted of 15 mM ammonium acetate adjust-
ed to pH 5.0 with acetic acid and acetonitrile in a 2:1 ratio
(v/v). Separation was achieved using an Altima HP C18-
Amide HPLC column (5 μm, 150 × 4.6 mm) from Grace
Alltech (Breda, The Netherlands). The injector was from
Waters (Etten-Leur, The Netherlands). The LC pump (LC-
10 ADVP) was obtained from Shimadzu (‘s-Hertogenbosch,
The Netherlands). The ultraviolet (UV) detector (Spectroflow
757) was obtained from Applied Biosystems (Waltham,
Massachusetts) and was used at a wavelength of 210 nm.
Data acquisition was achieved using Empower software from
Waters (Etten-Leur, The Netherlands).
Remoxipride
SPE-LC Method. For the precipitated plasma samples, on-line
SPE was combined with HPLC and mass spectrometry ac-
cording to Stevens et al (26). Briefly, a pretreated sample was
loaded into a Hysphere GP resin cartridge column
( 1 0 × 2 mm ) f r om S p a r k H o l l a n d ( Emm e n ,
The Netherlands) at pH 8.3 and flushed for 1 min. Elution
was performed using a low pH and an AltimaHPC18 column
(150 × 1.0 mm, 5 μm).
LC-Method. For microdialysates, a Kinetex 2.6 μm column
(50 × 2.0 mm, XB-C-18) from Phenomenex (Utrecht,
The Netherlands) was used at a flow of 0.6 ml/min and placed
at 40 oC. The system was a Nexera-X2 UHPLC system,
consisting of two ultra high performance liquid chromatogra-
phy (UHPLC) pumps delivering the high pressure gradient. A
SIL-30 AC auto sampler was used to inject 5 μl of the micro-
dialysis sample. The flow was diverted for the first 0.5 min,
while a gradient from 10 to 90% methanol in 1.5 min served
to elute both remoxipride and raclopride to the mass
spectrometer.
Mass Spectrometry
For risperidone, paliperidone and remoxipride, mass spec-
trometry was used to measure the concentrations. The mass
spectrometer was a TSQ Quantum Ultra from Thermo
Fisher Scientific (Breda, the Netherlands) and was used in
MS/MS mode. Electrospray was used for ionization in the
positive mode, nitrogen served as the desolvation gas and ar-
gon was used as collision gas. Data acquisition for both
remoxipride and risperidone and paliperidone was performed
using LCQuan 2.5 software from Thermo Scientific (Breda,
The Netherlands).
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Risperidone and paliperidone had the following transitions
(m/z): 411.2→191.1 (risperidone), 415.2 →195.1
(paliperidone), 415.2 →195.1 (risperidone-D4), 431.2
→211.1 (paliperidone-D4). The scan width was set at
0.2 m/z, the scan time was 0.05 s. Collision was performed
at fixed voltages between 27 and 38 V, using a skimmer offset
of 2 V.
The transitions (m/z) were 371→242.8 for remoxipride
and 247.0→84.0, 112, 218.8 for raclopride. The skimmer
offset was 18 and collision was performed between at fixed
voltages between 24 and 45 V. Scan width and scan time were
the same as above.
Determination of Fraction Unbound in Plasma
To determine the free fraction of paliperidone and risperi-
done in plasma samples, Centrifree Ultrafiltration Devices
from Merck Millipore (Amsterdam, The Netherlands) were
used to separate the free from the protein bound risperidone
and paliperidone in pooled plasma samples. Both the ultrafil-
trate and the original pooled plasma sample (without ultrafil-
tration step) were measured. The free fraction was calculated
according to the following Eq. 1:
Free fraction ¼ Ultrafiltrate concentration
Pooled plasma concentration
ð1Þ
For phenytoin and remoxipride, the free fraction in plasma
was calculated using a protein binding constant of 91 and
26% respectively which were obtained from literature (27,28).
Determination of In-Vivo Recovery (retro dialysis) (29)
The in-vivo recovery of paliperidone, risperidone phenytoin
and remoxipride was calculated using the compound concen-
tration in the dialysate (Cdial) and in PF (Cin) according to the
following Eq. 2:
In vivo recovery ¼ Cin−Cdial
C in
ð2Þ
Brain microdialysis data of paliperidone, risperidone, phe-
nytoin and remoxipride were corrected for in-vivo recovery to
obtain brainECF and CSF data.
The in-vivo recovery and free fraction for the nine com-
pounds are summarized in Table SII.
Human Data
Table II summarizes the clinical concentration data for acet-
aminophen and morphine used to assess model performance
to predict human concentrations. These data consisted of two
clinical studies for acetaminophen and two studies for mor-
phine. All studies were published, except for study 1 for
acetaminophen that consists of newly generated data (see in
Table II).
Acetaminophen
Acetaminophen human plasma samples and CSF samples
were obtained at Poitier University Hospital. Seven patients
who had a traumatic brain injury (TBI) were enrolled in the
clinical study. They were treated with a 30 min intravenous
infusion of 1 g of acetaminophen. CSF samples were collected
from a compartment of cerebrospinal fluid in the lateral ven-
tricle (CSFLV) by external-ventricular drainage (EVD) to con-
trol the intra-cranial overpressure (named CSFEVD) (30). All
clinical studies were conducted according to the Declaration
of Helsinki, and written informed consent was obtained from
each subject after the approval of the institutional review
board at the medical institute. The demographic data is sum-
marized in Table SIII. Acetaminophen concentrations at the
start of the study (some patients already received acetamino-
phen before) were used as an initial value in the plasma com-
partment. The volume of EVD samples and EVD flow rate
during a certain time interval were experimentally determined
(Table SIV).
A second human acetaminophen PK dataset (study 2) in
plasma and in CSF subarachnoid space (CSFSAS) was obtain-
ed from the literature, and was based on patients with nerve-
root compression pain (31).
For both datasets, total plasma concentrations for acet-
aminophen were converted to free plasma concentrations
using the free fraction obtained from literature (32).
Morphine
Morphine human concentration-time profiles in plasma and
in brainECF were obtained from the physiologically Bnormal^
side of the brain and also from the Binjured^ side of the brain
of TBI patients (33,34). For both datasets, the unbound plas-
ma concentrations were already reported in the original pub-
lications (33,34).
Software
The PK analysis was performed using NONMEMversion 7.3
(ICON Development Solutions, Hanover, MD, USA) (35).
For the brain PK modeling of rat data, the extended least
squares estimation method was applied. Other analyses were
performed by using the first-order conditional estimation
method with interaction (FOCE-I). The compartmental
models were defined using the ADVAN6 differential equation
solver in NONMEM (35). The plots and the statistical analysis
were conducted using R (Version 3.2.5; R Foundation for
Statistical Computing, Vienna, Austria) (36).
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Model Development
Separatemodels describing plasma and brain concentration-time
profiles for all nine compounds were developed whereby plasma-
and brain-related parameters were estimated simultaneously. A
naïve pooling approach was used (37), i.e. inter-individual vari-
ability in each compound’s data was not quantified, because of
the highly standardized experimental settings combined with the
homogeneous nature of the animals within each study.
The structural model that was used as a starting point was
based on our previously developedmodels (23–25). To develop
a more generally applicable model structure with parameters
that can be precisely estimated across drugs, we systematically
assessed the following two model structure characteristics.
First, a combined drug dispersion parameter was estimated
to capture the CSF and ECF flow and turbulence flow of the
drug molecules (38,39).
Second, drug transfer across the BCSFB was excluded.
SABCSFB is 2–15 times smaller than SABBB (40–42), suggesting
that drug exchange at BCSFB can be ignored from the model.
We evaluated for each drug the validity of the changes to
the basic model with regard to a single or two different flow
rates for drug dispersion and drug transport at the BCSFB.
Quantification of Active Drug Transport
For the 6 compounds, data were obtained using co-
administration of inhibitors of active transport. For all these
compounds, the effect of the active transport inhibitors was
tested on drug exchange at the BBB (QPL_ECF) and plasma
clearance (CLPL), and in combination, as a categorical covar-
iate. (Eq.3)
P ¼ PPAT  1þ θcov⋅Covð Þ ð3Þ
where PPAT represents the parameter including passive
and active transport (net transport), P represents the
parameter which takes into account the active transport
inhibitors if there is any such effect, Cov is the value of
the covariate (0: without an active transport inhibitor, 1:
with an active transport inhibitor), θcov represents the
effect of the active transport inhibitor.
Model Evaluation
The systematic inclusion of aforementioned factors was
guided by a likelihood ratio test, by an adequate param-
eter estimation precision, by assessment of the parameter
correlation matrix to ensure parameter identifiability, and
by the graphical evaluation of plots for observations versus
predictions and weighted residuals versus time and versus
predictions. The likelihood ratio test is based on the as-
sumption that changes in the NONMEM objective func-
tion values (OFV, -2 log likelihood) are asymptotically chi-
square distributed. A decrease of OFV ≥ 3.84 was consid-
ered statistically significant (p < 0.05). For a clear
Table II Summary of the Human Acetaminophen and Morphine Data
Study design Acetaminophen Morphine
Study 1 Study 2 Study 1 Study 2
Condition of patients human with traumatic
brain injury
human with nerve-root
compression pain
human with traumatic
brain injury
human with traumatic
brain injury
Nr of patients 7 1 (mean values) 2 1
Dosage 1 g, 30 min infusion 2 g (propacetamol),
short infusion
10 mg, 10 min infusion 10 mg, 10 min infusion
Nr of samples
(sampling time, h)
plasma 38 (0–6 h) 11 (0–12 h) 23 (0–3 h) 11 (0–3 h)
brain ECF or CSF 54 (0–5.5 h) 11 (0–13 h) 74 (0–3 h) 37 (0–3 h)
data references Newly generated (31) (34) (33)
Data
plasma X X X X
brainECF X (Bnormal^ and Binjured^
brain tissue)
X (Bnormal^ and Binjured^
brain tissue)
CSFEVD X
CSFSAS X
fp
a 85% 85% – –
fp references (32) (32) (34) (33)
brainECF a brain extracellular fluid compartment, CSFEVD a compartment of cerebrospinal fluid in EVD, CSFSAS a compartment of cerebrospinal fluid in subarachnoid
space
a free fraction in plasma
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assessment of model predictions and observations we also
computed the following metrics (Eq.4 and 5).
PE ¼ Y OBS;i j−Y PRED;i j
Y OBS;i j−Y PRED;i j
.
2
ð4Þ
SMAPE ¼ 1
N
X N
k¼1 PEj j  100 ð5Þ
where PE is a prediction error, and SMAPE is symmetric mean
absolute percentage error (43). YOBS,ij is the jth observation of
the ith subject, YPRED,ij is the jth prediction of the ith subject. N
is number of observations. In the cases where we did not esti-
mate inter-individual variability, e.g. for all brain PK data,
YPRED,ij equals the mean population prediction YPRED,j.
External Model Validation
Validation of the brain PK model was performed by investigat-
ing the quality of the prediction of external rat data. The predic-
tionwas done as follows, 1) estimating plasma-related parameters
(CLPL, QPL-PER1 VPL and VPL_PER1) using the external rat plas-
ma data, 2) fixing the brain-related parameters (QPL_ECF,QDIFF,
VECF, VLV, VTFV, VCM, and VSAS) to the values which were
estimated from the brain PK model and 3) predicting the
brainECF or CSF concentrations using estimated rat plasma-
related parameters and fixed brain-related parameters.
Plasma PK Analysis of External Rat Data
The plasma-related parameters including inter-individual
variability on these parameters and residual errors were esti-
mated using the external rat plasma data. We used a mixed
effects modeling approach to investigate the predictability of
the brain concentration based on each plasma concentration.
The same plasma model structure, which was obtained from
the brain PK model was applied for each compound. Inter-
individual variability were tested on each PK parameter using
an exponential model (Eq. 6).
θi ¼ θ  eηi ð6Þ
where θi represents the parameters of the ith subject, θ repre-
sents the populationmean value of the parameter, and ηi is the
random effect of the ith subject under the assumption of a
normal distribution with amean value of 0 and variance ofω2.
A proportional error model and the mixed error model
(Eq. 7-8) were tested for the residual errors:
Ci j ¼ Y PRED;i j  1þ εi j
  ð7Þ
Ci j ¼ Y PRED;i j  1þ ε1;i j
 
þ ε2;i j ð8Þ
where Cij represents the jth observed concentration of the ith
subject, YPRED,ij represents the jth predicted concentration of
the ith subject, and εij is the random effect of the jth observed
concentration of the ith subject under the assumption of a
normal distribution with a mean value of 0 and variance of σ2.
Model selection was guided by a likelihood ratio test with
p< 0.05 and by the precision of the parameter estimates.
Handling of the Brain-Related Parameter Values
For QPL_ECF, QDIFF, the same values, which were estimated
from the brain PK model, were used for acetaminophen and
remoxipride, respectively. VECF, VLV, VTFV, VCM, and VSAS
are system-specific parameters, therefore, the same rat physi-
ological values were used, indicated in Table III.
Prediction of brainECF and CSF Concentrations of External Data
Simulations were performed 200 times for each compound.
The 95% prediction interval (using the calculated 2.5% tile
and 97.5% tile) and the median of the simulated concentra-
tions were plotted together with the external data. Accuracy of
the mean population prediction for brain PK data was evalu-
ated with SMAPE mentioned above (Eq. 5).
Translation of the Model to Humans
The translational prediction was performed by the following
steps, 1) estimating plasma-related parameters (CLPL, QPL-
PER1 VPL and VPL_PER1) using human plasma data, 2) replac-
ing brain-related system-specific parameters (VECF, VLV,
VTFV, VCM and VSAS) by human values, 3) applying allome-
tric scaling to the brain-related drug-specific parameters
which were estimated with the rat in-vivo data (QPL_ECF and
QDIFF), 4) adding clinical sampling procedure related fixed
parameters which were obtained from the EVD into the mod-
el (QLV_EVD and VEVD) and 5) predicting the brainECF and
CSF concentrations using estimated human plasma PK pa-
rameters, replacing system-specific parameters, scaling drug-
specific parameters and using clinical sampling procedure re-
lated fixed parameters. The details of the translational
methods for each parameter are explained in Fig. 2.
Human Plasma PK Analysis
Plasma-related parameters including inter-individual variabil-
ity and residual errors were estimated using the human data
using the Eqs. 6–8. A 1-compartment, 2-compartment and 3-
compartment model were tested. Model selection was guided
by a likelihood ratio test with p< 0.05, by the precision and
correlation between parameter estimates and by the graphical
evaluation of plots for observations versus predictions and
weighted residuals versus time and versus predictions.
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Replacement of the System-Specific Parameters
System-specific parameters in the brain distribution rat model
(VECF, VLV, VTFV, VCM and VSAS) were replaced with the
human physiological values, which are available from litera-
ture (44–50) (see Table IV).
Scaling of the Drug-Specific Parameters
Drug-specific parameters (CLPL_ECF and QDIFF) were scaled
to human values using allometric principles following Eq. 9
(18).
Phuman ¼ Prat  BW humanBW rat
 0:75
ð9Þ
where Phuman is the scaled human parameter, Prat is the esti-
mated rat parameter from the model, BWhuman is the average
human body weight (70 kg), and BWrat is the average rat body
weight (250 g).
Adding Clinical Sampling Procedure Related Fixed Parameters
In addition to those parameters which were used in the rat
brain PK model, we have data obtained from the EVD ap-
proach, therefore the EVD compartment was added into the
translated brain distribution model (see Fig. 2). To describe
the PK of acetaminophen in the EVD compartment, the
values of flow rate from CSFLV to CSFEVD (QLV_EVD) and
the volume of EVD compartment (VEVD) were added into the
model. The values of QLV_EVD and VEVD for each patient are
obtained from EVD approach and available in Table SIV.
Prediction of Human brainECF and CSF Concentrations
Simulations were performed using the same methods as we
mentioned for the external model validation.
RESULTS
The analysis work flow is depicted in Fig. 3. The devel-
oped multi-compartmental brain PK model adequately de-
scribed the data for the nine compounds, as can be ob-
served from the selected observed and predicted
concentration-time profiles (Fig. 4a) and the prediction er-
ror plots for all of the nine compounds (Fig. 4b). The
prediction errors were mostly within two standard devia-
tions of zero, i.e. no systematic differences between obser-
vations and predictions were found. No specific trend
across time, also with respect to the presence or absence
of active transport inhibitors, were observed. More exten-
sive plots for individual observations versus predictions and
weighted residuals versus time across drugs, dose levels
and active transport inhibitors, are provided in the supple-
mental material (Figure S1 and S2).
We identified a generally applicable model structure
(Fig. 2) with physiologically relevant compartments. The final
model consists of plasma, brainECF, brain intracellular fluid
compartment (brainICF), CSFLV, compartment of CSF in
third and fourth ventricle (CSFTFV), compartment of CSF in
cisterna magna (CSFCM) and CSFSAS, which included pro-
cesses for drug exchange at the BBB (QPL_ECF) and drug dis-
persion through brainECF and CSF compartments (QDIFF).
The parameter estimates were obtained with good precision,
and are summarized in Table III.
A single drug dispersion rate (QDIFF) was shown to be suf-
ficient for describing the sum of the drug distribution in the
brainECF and CSF for the nine compounds. QDIFF was com-
parable among the compounds, and ranged between
0.0598 mL/min for methotrexate to 0.0133 mL/min for phe-
nytoin, and could be precisely identified (RSE < 15.0%), sug-
gesting this parameter could be potentially considered to rep-
resent a system-specific parameter.
The parameter representing drug transfer at the BBB
(QPL_ECF) was critical to quantify drug exchange between
blood and brain. QPL_ECF was substantially different between
plasma
periphery 1
CSFSAS
CSFCM
CSFTFV
CSF LV
brainECF
QDIFFSCALED
QDIFFSCALED
brainICF
periphery 2
QDIFFSCALED
QDIFFSCALED
Q DIFFSCALED
QPL_ECFSCALEDQPL_PER2EST
CLPLEST
QECF_ICFSCALED
QLV_PLSCALED
QPL_PER1EST VICFREP
VECFREP
VCMREP
VTFVREP
VLVREP
VSASREP
VPLEST
VPER1EST
VPER2EST
CSFEVD
QLV_EVDEXP
VEVDEXP
Model structure
Dashed line: parameter/compartment taken into account if needed
Required for human EVD data
Data availability
Rat data
Human data
Model parameters
Plasma-related parameter
Brain-related parameter drug-specific parameter
Brain-related parameter system-specific parameter
Brain-related parameter clinical sampling procedure related fixed parameter
Scaling methods to human data
EST: Estimation using plasma data
SCALED: Scaling with allometric principle
REP: Replacement with human physiological values
EXP: Use clinical sampling procedure related fixed parameter
Fig. 2 The brain PK model
structure and translational methods
for each parameter. The brain PK
model consists of plasma, brainECF,
brainICF, CSFLV, CSFTFV, CSFCM and
CSFSAS, which consists of 4 different
categories parameters (colors). The
scaling method on each parameter
is indicated with color coding.
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drugs, ranging from 0.0354 mL/min for quinidine to
0.00109 mL/min for methotrexate.
On the other hand, drug exchange at BCSFB was identi-
fied only for methotrexate, and could not be identified for the
other 8 compounds. For methotrexate, the efflux transport at
BCSFB (QLV_PL) was 0.105 mL/min.
Among the nine compounds, clearance between brainECF
and brainICF (QECF_ICF) could be estimated for paliperidone
and quinidine: QECF_ICF is 0.0250 mL/min for quinidine, and
0.0126mL/min for paliperidone, implying for quinidine a slight-
ly faster uptake into brainICF after crossing the BBB (Table III).
For morphine, brainECF concentration displayed a nonlin-
ear relationship with dose and plasma concentrations. A cat-
egorical dose effect was therefore estimated. Continuous line-
ar or nonlinear concentration-dependent effects to account for
this effect were not supported by the data.
No statistically significant impact of P-gp and the combina-
tion of MRPs, OATs andOATPs on CLPL could be identified,
whereas those transporters were identified to act as efflux trans-
porters at the BBB for our compounds. The P-gp function was
quantified on the data of morphine, paliperidone, phenytoin,
quinidine, and risperidone, and the impact of the combination
of MRPs, OATs and OATPs was quantified on the data of
methotrexate, as a categorical covariate onQPL_ECF. The pres-
ence of P-gp inhibitors increased the QPL_ECF values of mor-
phine, paliperidone, phenytoin, quinidine, and risperidone by
162, 43.4, 35.5, 443 and 124% respectively. The presence of
the inhibitor of MRPs, OATs and OATPs increased the
QPL_ECF values of methotrexate by 409%.
The developed model adequately predicted the external
rat acetaminophen and remoxipride data. Figure 5 presents
the prediction results for the external rat data of
Table IV Parameter Values used
for the Translational Prediction to
Humans
Translational methods Unit Parameter estimates (RSE, %)
Acetaminophen Morphine
Plasma-related parameters
CLPL estimation from human PK data mL/min 562 (20.1) 3070 (15.8)
QPL_PER1 estimation from human PK data mL/min 2060 (31.1) 3030 (0.60)
VPL estimation from human PK data mL 9880 (41.1) 16000 (35.3)
VPER1 estimation from human PK data mL 51900 (18.3) 95400 (2.50)
Brain-related parameters
Drug-specific parameters
QPL_ECF allometric scaling mL/min 1.92 FIX 0.513 FIX
QDIFF allometric scaling mL/min 3.81 FIX 1.37 FIX
System-specific parameters
VECF
a (44) replacement mL 240 FIX 240 FIX
VLV
a (45–47) replacement mL 22.5 FIX 22.5 FIX
VTFV
a (45–47) replacement mL 22.5 FIX 22.5 FIX
VCM
a (48,49) replacement mL 7.5 FIX 7.5 FIX
VSAS
a (50) replacement mL 90 FIX 90 FIX
Clinical sampling procedure related fixed parameters
QLV_EVD use the fixed parameter mL/min values are in supplemental Table IV
VEVD use the fixed parameter mL
Standard deviations of inter-individual variability (estimated from human PK data)
ω_CLPL 0.490 (30.2) 0.271 (19.9)
ω_QPL_PER1 NA NA
ω_VPL NA 0.596 (20.0)
ω_VPER1 0.235 (22.5) NA
Standard deviations of residual error (estimated from human PK data)
σ_plasma 0.250 (8.20) 0.0960 (22.9)
CLPL clearance from the central compartment, QPL_PER1 inter-compartmental clearance between the central compart-
ment and the peripheral compartment 1, VPL distribution volume of the central compartment, VPER1 distribution volume
of the peripheral compartment 1, QPL_ECF clearance from the central compartment to brainECF, QDIFF drug diffusion rate
in brain and CSF, VECF distribution volume of brainECF, VLV distribution volume of CSFLV, VTFV distribution volume of CSFTFV,
VCM distribution volume of CSFCM, VSAS distribution volume of CSFSAS, QLV_EVD flow fromCSFLV to CSFEVD, VEVD volume
of CSFEVD
a ; physiological values
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acetaminophen and remoxipride using the developed multi-
compartmental brain PK model. Prediction of the acetamin-
ophen concentration-time profile in brainECF using the final
model captured the external acetaminophen concentration in
brainECF well (SMAPE< 61%). Prediction of the remoxipride
concentration-time profile in brainECF, CSFLV and CSFCM
using the final model also captured the external remoxipride
concentrations in brainECF, CSFLV and CSFCM concentra-
tions well (SMAPE< 67, 77, 56%, respectively).
Themodel was successfully scaled to predict concentration-
time profiles of acetaminophen andmorphine in human brain
compartments. Table IV summarizes the parameter values
that were used for the prediction of human plasma,
CSFEVD, CSFSAS and brainECF. In Figure 6, the human pre-
dictions versus human observations are depicted. The acet-
aminophen human CSFSAS concentration in the patients with
nerve-root compression pain and CSFEVD concentration in
the patients with TBI were predicted relatively well
(SMAPE< 90 and 66% respectively), even though there is a
slightly faster elimination in CSFSAS. Morphine brainECF con-
centrations in the physiologically Bnormal^ brain tissue of TBI
patients were predicted very well (SMAPE< 35%). However,
morphine brainECF concentrations were underpredicted
when the brainECF concentrations were taken from Binjured^
brain tissue of TBI patients (SMAPE< 56%).
DISCUSSION
The developed multi-compartmental brain PK model could
describe the data of the nine compounds in the rat adequately
in the absence and presence of active transport blockers
(Fig. 4). After scaling of the model, human brain
concentration-time profiles of acetaminophen and morphine
could be adequately predicted in several physiological com-
partments under normal physiological conditions.
The model structure we have derived differs from the ones
published earlier by: (i) a combined drug dispersion parameter
was estimated to capture the CSF and brainECF flow and
turbulence flow of the drug molecules; and (ii) drug transfer
across the BCSFB was excluded (23–25). The final model has
four different CSF compartments. This model is developed to
predict human brain concentration profiles using rat data. In
our analysis, rat data was sampled from CSFLV and CSFCM.
Since in rats it is anatomically easier to access the CSFCM
compartment to obtain drug concentration by microdialysis
and by the cisternal puncture methods, there are more data
available from CSFCM (51). Through keeping the CSFCM
compartment in the model structure, it will be easier to apply
the model to additional compounds’ data obtained in animals.
Furthermore, substantial differences between CNS compart-
ments may exist, such as a concentration difference between
CSFLV and CSFCM for methotrexate and quinidine in rat
(24,25). Thus, to predict the drug target site concentration,
the location of the CSF sampling site should be taken into
account. For human, in clinical studies most CSF samples
are taken from other CSF compartments, such as CSFSAS
and CSFLV where samples are taken by EVD. Hence, we
think that our model structure is a minimal, necessary model
structure for translation.
We found that the brain intracellular fluid compartment
(brainICF) is required for the description of drug distribution of
quinidine and paliperidone, and likely associated with the li-
pophilic basic nature of quinidine (pKa 13.9, log P 3.4) and
paliperidone (pKa 13.7, log P 1.8). For other compounds with
a less distinct lipophilic-basic nature, such as for
Development of a rat brain PK  
model
External validation with the 
additional rat data 
Translation of a rat brain PK 
model to human 
Data
(black: published data, blue: new data)
Acetaminophen, Atenolol, Methotrexate, 
Morphine, Quinidine, Remoxipride, 
Paliperidone, Phenytoin, Risperidone
Acetaminophen, Remoxipride 
Acetaminophen, Morphine
Methodology
EST: estimation using plasma data
FIX: fixed to the values obtained from the model development
SCALED: scaling with allometric principle
REP: replacement with human physiological values
EXP: use clinical sampling procedure related fixed parameter
Plasma-related parameters: EST
Brain-related system-specific parameters: FIX
Brain-related drug-specific parameters: FIX
Plasma-related parameters: EST
Brain-related system-specific parameters: REP
Brain-related drug-specific parameters: SCALED
Brain-related parameter clinical sampling procedure related fixed parameter: EXP
Plasma-related parameters: EST
Brain-related system-specific parameters: FIX
Brain-related drug-specific parameters: EST
Fig. 3 Schematic flow chart of the analysis.
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acetaminophen and phenytoin, we have shown that brainICF
was not required for the description of concentration-time
profiles in the brain. However, for a generally applicable brain
PK model, inclusion of this compartment would still be re-
quired since prediction of intracellular drug concentrations
would be of relevance for CNS drug development as well as
prediction of extracellular drug concentrations. Our model
and the microdialysis methodology used only allow quantifi-
cation of extracellular concentrations. However, in combina-
tion with PBPKmodeling based principles to predict intracel-
lular partitioning, our model will be of significant relevance as
it provides the required predictions for unbound extracellular
drug concentration kinetics.
A drug exchange parameter across the BCSFB (QLV_PL)
was identified for methotrexate only, even though it could not
be identified for the other 8 compounds. This suggests that an
additional efflux transporter might be present at the BCSFB
for which methotrexate is a substrate. It is known that meth-
otrexate is indeed a substrate of various transporters, such as
RFC1, MRP, BCRP, OATP and OAT transporters (25),
which are not involved in the drug transfer of the other 8
compounds. This result indicates that drug transport at
Fig. 4 Prediction of the multi-compartmental brain PK model. (a) Individual observed drug concentrations (lines and circles) and mean model prediction (solid
lines). Unbound concentration (ng/mL) versus time (min) profiles for acetaminophen and morphine. (b) Box-whisker plots for the prediction errors across all nine
drugs evaluated. The plots were stratified by brain compartments (panels) and by active transport blockers (colors).
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Fig. 5 Model prediction versus external acetaminophen and morphine data in rat. Individual concentration-time profile of the external data (circles) and
prediction from the brain PK model (red lines: median, shaded area is 95% prediction interval). (a) Acetaminophen data were obtained after 200 mg admin-
istration, (b) remoxipride data were obtained from the dose group of 0.7, 5.2 and 14 mg/kg. The x-axis represents the time in minutes and the y-axis represents
the dose-normalized acetaminophen and remoxipride concentration. The panels are stratified by brain compartments and compounds.
Fig. 6 Human brainECF and CSF
concentration-time profiles (circles)
and prediction from the translational
model (red lines: median, shaded
area is 95% prediction interval). (a)
Acetaminophen data was obtained
from plasma, CSFSAS and CSFEVD,
(b) morphine data was obtained
from plasma and brainECF in
Bnormal^ brain and Binjured^ brain.
The x-axis represents the time in
minutes and the y-axis represents
the acetaminophen and morphine
concentration in ng/ml. The panels
are stratified by brain compartments
and brain conditions.
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BCSFB still needs to be investigated using data on compounds
which are substrates for those transporters. The current model
delineates the process that can be used to arrive to the best-
performing model for such drugs. We took care to design the
modeling process such that the total number of models that
need to be fitted is minimal.
We identified a drug dispersion rate parameter that captures
drug dispersion from brainECF to CSF. The median estimated
drug dispersion flow was 0.0237 mL/min. The magnitude of
the drug dispersion rate was approximately ten times faster
than the reported physiological CSF flow rate alone (52), and
about 100 times faster than the reported physiological brain
ECF bulk flow rate (53,54). Since similar values across drugs
were identified, the parameter may be considered a system-
specific parameter that could be fixed in further analyses (see
Table III), to allow for estimation of other processes of interest.
P-gp transport for quinidine, risperidone, paliperidone,
morphine and phenytoin was confirmed as efflux transporter
at the BBB which were in line with literature (55,56). P-gp
transporter effects were not identified at the BCSFB for these
5 P-gp substrates, i.e. CSF concentrations for these com-
pounds were well-described solely by the BBB mediated P-
gp transport. The role and contribution of P-gp transporters
at the BCSFB is still inconsistent, and both efflux and influx
processes have been reported (57–59). Our results however
suggest that the function of P-gp may be ignored, since its
potential magnitude likely is negligible compared to transport
at the BBB, and drug dispersion processes prevail.
Nonetheless, overall, we envision that the combination of
our dynamical modeling approach with the incorporation of
in-vitro assays to characterize active transport across the BBB
or BCSFB, may be a fruitful direction to further characterize
and disentangle the precise contribution to the brain drug
disposition of different drug transport.
The developed model adequately predicted the external
acetaminophen and remoxipride rat data, confirming the reli-
ability of the model. Both of these drugs were also used for
model development, but the experiments were different and
applied somewhat different designs. Since we aimed to gener-
ate mean predictions, the variation in numbers of animals is
expected to result in limited bias in the modeling. Furthermore,
sampling time points were very informatively distributed and
any inter-experimental differences in these time points are
therefore also considered to be of limited impact on model
development. The external validation results indicated that
the model is robust with respect to variations in experimental
designs and conditions (i.e. the number of rats, sampling times,
infusion times, and flow rates of microdialysis).
We consider the developed model structure suited for
translational predictions of human brain (target site) concen-
trations such as required during drug development. The pre-
dictive performance in human data ranged between SMAPE
of 35–90%. Even though errors <90% may appear large,
such < two-fold error is not considered unacceptable when
compared to for instance QSAR studies, which are used to
predict unbound brain partition coefficients of drugs in drug
development (60,61). Secondly, the prediction error is likely
inflated because of the use of human data obtained from pa-
tients with traumatic brain injury or with nerve-root compres-
sion pain. Therefore, larger variability in their physiological
condition is expected.
Body weight in combination with allometric scaling
was used to scale the parameters to humans, and this
resulted in adequate predictions of human brain concen-
trations for physiologically Bnormal^ brains. Different
translational methods for estimation of CNS PK parame-
ters have been reported in the literature. For instance,
system-based scaling was applied using volume of brain
tissue or brain endothelial surface area (25,62), but allo-
metric scaling using body weight (our approach) was sup-
ported by work from others in the literature (63–66).
Based on our current approach, reasonable predictions
were obtained. Therefore, we suggest that the allometric
scaling approach may indeed be appropriate although it
would be worthwhi le to inves t igate a l ternat ive
approaches.
Our model was developed based on healthy rats and
then translated to human data that was partly based on
patients with severe brain injuries. Indeed, observed hu-
man morphine concentrations in brainECF obtained from
the Binjured^ side of the brain of the TBI patients was
higher than the prediction from the translational model
(Fig. 6). It is known that the BBB permeability is increased
after TBI, which may be the reason for the under-
prediction of our translational model for those data
(67,68). Therefore, for predictions in patients with patho-
logical conditions that alter the integrity of BBB or
BCSFB barriers, or brain fluid flows, our model should
be further extended with additional physiological details.
CONCLUSION
A multi-compartmental brain PK model structure was devel-
oped across a wide range of drugs with different physicochemical
properties. Themodel structure was shown to be of relevance for
the scaling of brain concentrations in humans. As such, the de-
veloped model structure can be used to inform the prediction of
relevant target site concentrations in humans and aid in the
translational development of CNS targeted drugs.
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